Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Morgan Stanley
Tweet
Share
E-mail
Get Alerts BHVN Hot Sheet
Price: $14.64 --0%
Rating Summary:
17 Buy, 7 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 18
Rating Summary:
17 Buy, 7 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 18
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $63.00 (from $69.00) while maintaining a Overweight rating.
The analyst comments "Post 4Q we update our BHVN model as we remove BHV-7000 (Kv7 activator) sales for bipolar and update for 4Q expense trends and 10-K filing. The primary focus for the stock remains on FDA action on Troriluzole in SCA, and we are OW rated."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Celcuity Inc (CELC) PT Raised to $175 at Guggenheim
- Wedbush Starts Immunic Inc. (IMUX) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Morgan Stanley, Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
